Your browser doesn't support javascript.
Vitamin C and COVID-19 treatment: A systematic review and meta-analysis of randomized controlled trials.
Rawat, Dimple; Roy, Avishek; Maitra, Souvik; Gulati, Arti; Khanna, Puneet; Baidya, Dalim Kumar.
  • Rawat D; Clinical Epidemiology Unit, All India Institute of Medical Sciences, New Delhi, India. Electronic address: rawat.dimple96@gmail.com.
  • Roy A; Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India. Electronic address: roy.avishek1992@gmail.com.
  • Maitra S; Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India. Electronic address: souvikmaitra@live.com.
  • Gulati A; Clinical Epidemiology Unit, All India Institute of Medical Sciences, New Delhi, India. Electronic address: gulatiarti@yahoo.co.uk.
  • Khanna P; Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India. Electronic address: k.punit@yahoo.com.
  • Baidya DK; Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India. Electronic address: dalimkumar.ab8@gmail.com.
Diabetes Metab Syndr ; 15(6): 102324, 2021.
Article in English | MEDLINE | ID: covidwho-1555992
ABSTRACT
BACKGROUND AND

AIMS:

Vitamin C has been used as an anti-oxidant in various diseases including viral illnesses like coronavirus disease (COVID-19).

METHODS:

Meta-analysis of randomized controlled trials (RCT) investigating the role of vitamin C supplementation in COVID-19 was carried out.

RESULTS:

Total 6 RCTs including n = 572 patients were included. Vitamin C treatment didn't reduce mortality (RR 0.73, 95% CI 0.42 to 1.27; I2 = 0%; P = 0.27), ICU length of stay [SMD 0.29, 95% CI -0.05 to 0.63; I2 = 0%; P = 0.09), hospital length of stay (SMD -0.23, 95% CI -1.04 to 0.58; I2 = 92%; P = 0.57) and need for invasive mechanical ventilation (Risk Ratio 0.93, 95% CI 0.61 to 1.44; I2 = 0%; P = 0.76). Further sub-group analysis based on severity of illness (severe vs. non-severe), route of administration (IV vs. oral) and dose (high vs. low) failed to show any observable benefits.

CONCLUSION:

No significant benefit noted with vitamin C administration in COVID-19. Well-designed RCTs with standardized control group needed on this aspect.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ascorbic Acid / COVID-19 Drug Treatment / Antioxidants Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Traditional medicine Limits: Humans Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ascorbic Acid / COVID-19 Drug Treatment / Antioxidants Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews / Systematic review/Meta Analysis Topics: Traditional medicine Limits: Humans Language: English Journal: Diabetes Metab Syndr Year: 2021 Document Type: Article